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Abstract
Background: Uterine leiomyomas, or fibroids, represent the most common benign tumor of the female reproductive tract.
Fibroids become symptomatic in 30% of all women and up to 70% of African American women of reproductive age.
Epigenetic dysregulation of individual genes has been demonstrated in leiomyoma cells; however, the in vivo genome-wide
distribution of such epigenetic abnormalities remains unknown.
Principal Findings: We characterized and compared genome-wide DNA methylation and mRNA expression profiles in
uterine leiomyoma and matched adjacent normal myometrial tissues from 18 African American women. We found 55 genes
with differential promoter methylation and concominant differences in mRNA expression in uterine leiomyoma versus
normal myometrium. Eighty percent of the identified genes showed an inverse relationship between DNA methylation
status and mRNA expression in uterine leiomyoma tissues, and the majority of genes (62%) displayed hypermethylation
associated with gene silencing. We selected three genes, the known tumor suppressors KLF11, DLEC1, and KRT19 and
verified promoter hypermethylation, mRNA repression and protein expression using bisulfite sequencing, real-time PCR and
western blot. Incubation of primary leiomyoma smooth muscle cells with a DNA methyltransferase inhibitor restored KLF11,
DLEC1 and KRT19 mRNA levels.
Conclusions: These results suggest a possible functional role of promoter DNA methylation-mediated gene silencing in the
pathogenesis of uterine leiomyoma in African American women.
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Introduction
Uterine leiomyomas or fibroids are benign smooth muscle
tumors of myometrial origin; despite their benign nature, they are
able to undergo rapid and considerable growth [1]. Uterine
leiomyomas are the most common gynecological tumors in women
of reproductive age, and they become symptomatic in 25–30% of
all women and in up to 70% of African American women of
reproductive age [2]. Compared with white women, African
American women are 3 times more likely to develop symptomatic
leiomyoma, which also develops at earlier ages with more
numerous and larger fibroids [3]. The clinical symptoms
associated with uterine leiomyoma are abnormal uterine bleeding,
which can lead to anemia, pelvic pressure and pain; reduced
fertility; and frequent pregnancy loss [4]. In the United States,
600,000 hysterectomies are performed each year; of these,
approximately 40% are performed to treat uterine leiomyoma.
The surgical costs alone represent an economic burden of $2
billion per year [5], and when taking into account the social costs
and associated long-term health problems, it is clear that better
prevention and treatment options for women with uterine
leiomyoma are urgently needed. Understanding the molecular
mechanisms underlying the pathogenesis of uterine leiomyoma
will facilitate the discovery and development of new approaches to
the treatment of this disease.
Gene expression profile studies have demonstrated that
hundreds of genes with critical functions in differentiation,
apoptosis, proliferation and extracellular matrix formation are
dysregulated in uterine leiomyoma [6]. Currently, a few
cytogenetic aberrations in specific genes have been discovered
[7]; however, it remains unknown whether these dysregulated
genes act as effectors or growth promoters in uterine leiomyoma.
Epigenetic mechanisms such as DNA methylation, histone
modification, and non-coding RNAs are described as heritable
changes in gene expression not associated with changes in the
primary DNA sequence; rather, these changes affect secondary
interactions that play a crucial role in the regulation of gene
expression. In the mammalian genome, DNA methylation is the
most common and well-characterized epigenetic mark, which
consists of the covalent addition of a methyl group to the 59-carbon
of the cytosine ring within the context of CpG dinucleotides
following replication. The methylation of this cytosine is catalyzed
by specific DNA methyltransferases (DNMTs), which transfer a
methyl group, from the donor S-adenosyl methionine (SAMe) to
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that there is differential expression of DNMTs in uterine
leiomyoma and that there is aberrant DNA methylation in uterine
leiomyoma compared with normal myometrial tissue [9–10]. One
study demonstrated that hypomethylation of ESR1 in uterine
leiomyoma correlates with increased mRNA expression in uterine
leiomyoma [11]. These findings suggest that, DNA methylation
might play a key role in the pathogenesis of uterine leiomyoma by
altering the normal myometrial mRNA expression profile. Further
characterization of the role of epigenetics in the tumorigenesis of
uterine leiomyoma, requires an analysis of global, genome-wide
DNA methylation in disease and normal uterine tissue.
The objective of this study was to determine the relationship
between differential DNA methylation and mRNA expression in
uterine leiomyoma by performing a genome-wide analysis. We
sought to determine whether differentially regulated genes in
uterine leiomyoma versus adjacent normal myometrial tissue are
under epigenetic control. We attempted to identify a subset of
genes whose differential DNA methylation correlated with
differential mRNA expression. Our findings will advance our
understanding of the contribution of DNA methylation to the
pathogenesis of uterine leiomyoma.
Results
Analysis of DNA methylation and mRNA expression in
uterine leiomyoma and matched adjacent myometrial
tissue
We compared DNA methylation patterns in human uterine
leiomyoma and adjacent normal myometrial tissues from 18
women to identify genes that are differentially expressed and
epigenetically regulated. We used samples from African American
women to limit biological heterogeneity and avoid epigenetic
variation among ethnic groups; key clinical characteristics of
samples are described in Table 1. We performed a genome-wide
DNA methylation analysis using the high throughput Illumina
Infinium Human Methylation27 Beadchips in paired sets of
uterine leiomyoma and matched adjacent normal myometrial
tissues. The Illumina probes detect the methylation state of 27,578
individual CpG dinucleotides, located predominantly in CpG
islands within proximal promoter regions between 1.5 kb
upstream and 1 kb downstream of the transcription start sites of
14,475 consensus coding sequences genes throughout the human
genome [12]. To complement this approach, we also performed
parallel genome-wide mRNA expression profiling using the
Human Ht-12v3 expression beadchip, which targets more than
25,203 transcripts. These two platforms share approximately 66%
genes; thus, the majority of the human genes were represented in
our genome-wide analysis.
We first compared the DNA methylation patterns in uterine
leiomyoma versus adjacent normal myometrium following these
thresholds: fold change .2, P,0.001, and FDR (false discovery
rate),0.01. A total of 585 transcriptional regulatory regions were
hypermethylated, and 446 were hypomethylated in uterine
leiomyoma compared with adjacent normal myometrial tissue
(Figure 1A). We then analyzed mRNA expression patterns using
the following criteria: fold change .1.5, P,0.001 and
FDR,0.01. We found that 307 mRNA species were downregu-
lated, and 218 were upregulated in uterine leiomyoma compared
with myometrial tissue (Figure 1A). We then analyzed the
relationship between the DNA methylation of a transcriptional
regulatory region and mRNA expression of the gene in that
region. A total of 55 genes showed both differential DNA
methylation and changes in mRNA expression in uterine
leiomyoma and adjacent normal myometrial tissue (Figure 1A).
Compared with the myometrium, uterine leiomyoma contained
34/55 genes (62%) that were hypermethylated and transcription-
ally downregulated and 10/55 genes (18%) that were hypomethy-
lated and transcriptionally upregulated (Figure 1B). Thus, 44/55
genes (80%) showed an inverse correlation between promoter
region methylation and mRNA expression (Table 2 and 3). We
also observed that 15% of the overlapping genes were hyper-
methylated and transcriptionally upregulated, and a much smaller
number (5%) were hypomethylated and downregulated.
Patterns of differential DNA methylation and mRNA
expression in uterine leiomyoma and matched adjacent
myometrial tissues
We further analyzed the group of 55 genes that overlapped with
respect to differential DNA methylation and mRNA expression.
The majority of the 18 uterine leiomyoma samples exhibited a
homogeneous pattern of DNA hypermethylation, whereas the
normal myometrial samples were largely hypomethylated
(Figure 2A). Intriguingly, while differential mRNA expression in
the uterine leiomyoma and adjacent normal myometrial samples
exhibited a more heterogeneous pattern (Figure 2B), the pattern
was a mirror image of the differential DNA methylation pattern
(Figure 2A). We also performed a functional analysis of the 55
overlapping genes using Ingenuity Pathways Analysis (IPA) and
the Bioconductor GeneAnswers package, and found that based on
their p-values level, the top two most significantly enriched gene
functions are cancer processes (P,10
212) or reproductive system
diseases (P,10
28) [13]. The genes involved in cancer were
DLEC1, KRT19, KLF11, SERPINF1, TEK, APOLD1, LYVE1,
CCL2, IL17B, and TNFS10, and genes involved in reproductive
system diseases were CRIM1, PCP4, CHRDL2, HOXA5, PLP1,
COL9A2, SOX18, BMP, CALCRL, SFRP1 (Figure 2C).
Validation of differential DNA methylation using bisulfite
genomic sequencing
We hypothesized that the 55 overlapping genes with differential
DNA methylation and mRNA expression in uterine leiomyoma
compared with normal myometrium were likely to be true targets
of epigenetic regulation in uterine leiomyoma. Initially, we
examined the regulatory CpG islands in the promoter regions of
selected genes from the 55 candidates, and characterized the
positions of 59 CpG islands and transcriptional start sites using
available genome databases. From this set, we then selected three
of the hypermethylated genes, Kruppel-like transcription factor 11
(KLF11), deleted in lung and esophageal cancer 1 (DLEC1),
keratin 19 (KRT19) for further analysis based on their known
tumor suppressor functions.
First, we studied the KLF11 promoter via sequencing of
bisulfite-treated genomic DNA from uterine leiomyoma and
myometrial tissues from 8 subjects. Four of these were African
American that were included in our original genome-wide DNA
methylation study (#1–4), and we incorporated four new matched
samples from Caucasian subjects (# 5–8). We analyzed the DNA
methylation status of a cluster of 16 CpG dinucleotides across a
249-bp region of a CpG island, located approximately 2900 bp to
2500 bp upstream of the KLF11 promoter region (Figure 3A).
Four to six clones were sequenced from each subject. The detailed
CpG methylation level of primary leiomyoma (n=8) and matched
myometrial (n=8) tissues verified the hypermethylated state of the
KLF11 promoter in uterine leiomyoma compared with adjacent
normal myometrium. Six of the eight uterine leiomyoma samples
showed increased DNA methylation of the KLF11 promoter. In
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the KLF11 promoter were consistently methylated. There was a
significant statistical difference (P,0.004, Student’s t-test) in DNA
methylation levels between the uterine leiomyoma and matched
myometrial tissues (Figure 3B).
Then, we analyzed the promoter region of another tumor
suppressor gene, DLEC1, in uterine leiomyoma and myometrial
samples from 7 subjects. Three subjects were African Americans
included in our original genome-wide DNA methylation study
(#1–3), and we incorporated four new matched samples from
Caucasian subjects (#4–7). We sequenced a cluster of 18 CpG
dinucleotides across a 252-bp region of a CpG island located
within a 2100 to +150 bp region of the DLEC1 promoter
(Figure 3C). Uterine leiomyoma tissues demonstrated a dense
methylation pattern at the DLEC1 promoter region in 5 of the 7
subjects. The majority of the 18 CpG dinucleotides in the DLEC1
promoter were consistently methylated in uterine leiomyoma, but
not in normal myometrial tissues. Overall, there was a significant
statistical difference (P,0.003, Student’s t-test) in methylation
levels between uterine leiomyoma and matched normal myome-
trial tissues (Figure 3D).
Finally, we studied the KRT19 promoter via sequencing of
bisulfite-treated genomic DNA from uterine leiomyoma and
myometrial tissues from 7 subjects. Four subjects were African
Americans included in our original genome-wide DNA methyla-
tion study (#1–4), and we incorporated three new matched
samples from Caucasian subjects (#5–7). We analyzed the DNA
methylation status of a cluster of 30 CpG dinucleotides across a
300-bp region of a CpG island, located approximately 2150 bp to
2150 bp around the KRT19 promoter (Figure 3F). Four to six
clones were sequenced from each subject. The detailed CpG
methylation level of primary leiomyoma (n=7) and matched
myometrial (n=7) tissues verified the hypermethylated state of the
KRT19 promoter in uterine leiomyoma compared with adjacent
normal myometrium. All seven analyzed samples showed
increased DNA methylation of the KRT19 promoter. In uterine
leiomyoma, the majority of the 30 CpG dinucleotides in the
KRT19 promoter were consistently methylated. There was a
significant statistical difference (P,0.001, Student’s t-test) in DNA
methylation levels between the uterine leiomyoma and matched
myometrial tissues (Figure 3F). The Illumina platform covers
50 bp regions, whereas bisulfite sequencing evaluates a 250–
300 bp region, which overlaps with the 50 bp sequence of interest.
These longer fragments enhance fidelity.
Impact of DNA methylation on gene expression in
human uterine leiomyoma and matched adjacent
myometrial tissues
To validate that DNA methylation leads to gene silencing of
the tumor suppressor genes KLF11, DLEC1, and KRT19, we
assessed mRNA levels in vivo using real-time RT-PCR in uterine
leiomyoma and matched myometrial tissues. We performed real-
time RT-PCR on all 18 samples originally used in the microarray
analysis plus we incorporated 7–10 new samples from Caucasian
subjects. KLF11 mRNA levels in uterine leiomyoma (18 samples
from original microarrays and 7 new Caucasian samples) were
considerably lower (40%) than those in matched adjacent normal
myometrial tissues (n=25; P,0.0001, Figure 4A). DLEC1
mRNA levels in uterine leiomyoma tissues (18 samples from
original microarray and 10 new Caucasian samples) were also
significantly lower (60%) than those in matched myometrial
tissues (n=28; P,0.0001, Figure 4B). KRT19 mRNA levels in
uterine leiomyoma (18 samples from original microarray and 7
new Caucasian samples) were considerably lower (66%) than
those in matched adjacent normal myometrial tissues (n=25;
P,0.0001, Figure 4C). We have not observed any differences in
mRNA levels between samples from African- and Caucasian-
American subjects.
Table 1. Descriptive characteristics of subjects.
Subject No Age Weight (gm) Size
1 (cm) No of tumors in uterus Cycle phase (endometrium)
1 49 1500 10 10 Proliferative
2 43 1000 9 10 Proliferative
3 50 1140 6 10 Proliferative
4 45 950 6 10 Proliferative
5 40 800 5 10 Proliferative
6 35 1300 17 6 Proliferative
7 40 1300 12 5 Proliferative
8 45 750 10 5 Proliferative
9 48 450 8 5 Proliferative
10 50 440 6 5 Proliferative
11 30 700 16 3 Proliferative
12 38 2400 16 3 Proliferative
13 48 2500 12 3 Proliferative
14 42 440 7 1 Proliferative
15 50 600 7 10 Secretory
16 50 840 6 10 Secretory
17 47 1050 11 1 Secretory
18 42 1050 8 12 Disordered
1Size: largest diameter.
doi:10.1371/journal.pone.0033284.t001
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To determine whether the decrease in mRNA expression of
these three tumor suppressor genes is regulated by DNA
methylation, primary cultured leiomyoma smooth muscle cells
isolated from 7 new subjects not previously used in microarrays (4
subjects were African- and 3 Caucasian-American) were treated
with the DNMT inhibitor, 5-aza-dC at different concentrations
(0.5, 1, 3, 5, 10, 15, 20 mM) and time points (1, 3, 5 days). Real-
time RT-PCR was performed to measure KLF11, DLEC1, and
KRT19 mRNA levels. We observed that 5-aza-dC treatments at
various doses had a similar effect on restoring mRNA levels. We
chose the 3 mM dose to perform the subsequent experiments
because it was potentially less toxic to the cells while being
maximally effective. After analyzing mRNA expression after 1, 3
and 5 days, we determined that the effect is most effective at
restoring mRNA expression levels after 5 days of treatment. As
shown in Figure 5, 5-aza-dC treatment of primary cultured
leiomyoma smooth muscle cells led to an increase in KLF11
mRNA by 1.4-fold, DLEC1 mRNA by 2-fold, and KRT19
mRNA by 2.4-fold suggesting that these three genes are
epigenetically regulated in leiomyomas.
Protein expression in human uterine leiomyoma and
matched adjacent myometrial tissues
To understand the in vivo relevance of how DNA methylation
affects gene function, we analyzed protein levels of KLF11,
DLEC1 and KRT19 in human leiomyoma and matched normal
myometrial tissues using western blot. KLF11 protein levels in all 6
subjects were significantly lower (30%) in leiomyoma compared
with myometrial tissues (Figure 6A and D). Overall, DLEC1
protein levels were also significantly lower (30%) in leiomyoma
than in myometrial tissues, and only 2 out of 9 subjects had no
difference in DLEC1 expression in leiomyoma compared with
myometrial tissues (Figure 6B and E). KRT19 protein levels in 8
subjects were lower (25%) in leiomyoma than myometrial tissues,
and only 1 subject had higher KRT19 protein levels in leiomyoma
compared with myometrial tissues (Figure 6C and F). All protein
studies were performed with 6–9 new pairs of matched samples
not previously used in the microarray experiments; 5 subjects were
African American and 4 subjects were Caucasian. Overall, western
blots showed that KLF11 (n=6, P,0.0001), DLEC1 (n=9,
P,0.005) and KRT19 (n=8, P,0.03) (Student’s t-test). Protein
levels in leiomyoma tissues were significantly lower compared with
matched normal myometrial tissues.
Figure 1. Integration of DNA methylation and mRNA expression data in uterine leiomyoma and matched myometrial tissues. (A) The
Venn diagram integrates the number of differentially DNA methylated genes with the number of differentially expressed genes in leiomyomas
compared to myometrial tissues. Approximately 55 genes showed changes in methylation status and expression. (B) A total of 34 (62%) of the genes
were hypermethylated and downregulated, 10 (18%) were hypomethylated and upregulated, 8 (15%) were hypermethylated and upregulated and 3
(5%) were hypomethylated and downregulated.
doi:10.1371/journal.pone.0033284.g001
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Recent evidence suggests that DNA is differentially methylated
in uterine leiomyoma versus adjacent normal myometrial tissue;
however, these findings are predominantly reported in small
studies and analysis of individual candidate genes such as ESR1,
which has been shown to be hypomethylated in leiomyomas [9–
10]. We particularly paid attention to the ESR1 gene, but we did
not observe any differential DNA methylation patterns between
leiomyoma and myometrium. Hypomethylation of ESR1 in
leiomyoma was reported using a group of Japanese subjects; thus
the difference between our findings and theirs could be attributed
to racial differences. Similar racial differences have also been
reported for the aromatase mRNA levels and promoter usage in
uterine leiomyomas [14].
More recently published reports have attempted to demonstrate
differential DNA methylation in leiomyomas; one study examined
differences across the X chromosome in a single subject supporting
the concept of epigenetic regulation in uterine leiomyoma.
However, the other study was insufficient to identify differences
in DNA methylation, which could be due to the small number of
samples investigated [15–16]. Here, we report the first genome-
Table 2. Summary of hypermethylated, transcriptionally downregulated genes in uterine leiomyoma compared with adjacent
normal myometrium (N=18 matched samples).
Gene symbol Gene name DNA Methylation
1 P-value mRNA level
2 P-value
KRT19 Keratin 19 12.81 4.92E-10 22.5166 5.68E-05
NUAK1 NUAK family, SNF1-like kinase, 1 7.327 9.98E-07 21.5532 6.70E-06
KLF11 Kruppel-like factor 11 7.1816 1.40E-07 21.6765 1.32E-05
DLEC1 deleted in lung and esophageal cancer 1 6.3828 1.01E-07 21.51 1.44E-03
CORIN Corin, serine peptidase 5.9463 2.85E-09 21.5615 2.17E-05
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 isoform b 5.6828 4.02E-09 23.32 9.22E-06
MBP Myelin basic protein 5.5791 1.83E-06 21.7654 1.50E-04
TMEM173 Transmembrane protein 173 5.1523 7.89E-07 21.6351 2.56E-04
TNFSF10 Tumor necrosis factor (ligand) 4.9483 1.51E-08 21.9423 1.16E-07
BST2 Bone marrow stromal cell antigen 2 4.5596 9.82E-11 22.1626 1.44E-06
C1orf115 Chromosome 1 open reaing frame 115 3.9093 9.45E-07 21.7191 4.16E-08
HOXA5 Homeobox A5 3.7552 8.49E-08 21.7155 7.35E-06
TEK TEK tyrosine kinase, endothelial 3.7477 9.69E-09 21.8461 1.37E-06
RBP1 Retinol binding protein 1, cellular 3.686 1.10E-08 22.3092 1.14E-04
RASIP1 Ras interacting protein 1 3.5885 1.06E-11 21.7365 9.28E-05
GRAMD3 GRAM domain containing 3 2.8256 1.19E-05 21.5505 1.03E-05
CCDC109B Coiled-coil domain containing 109B 2.645 1.60E-05 21.5931 4.92E-05
APOLD1 Apolipoprotein L domain containing 1 2.6009 1.45E-12 21.9577 6.72E-05
CALCRL Calcitonin receptor-like 2.5571 2.18E-06 21.856 3.63E-07
SERPINF1 Serpin peptidase inhibitor, clade F 2.4166 3.88E-05 21.8676 9.71E-04
TM4SF1 Transmembrane 4 L six family 2.2707 7.66E-08 21.9102 3.64E-07
CD34 CD34 molecule 2.2474 1.41E-09 21.585 1.51E-05
CFB Complement factor B 2.2336 3.08E-04 21.9627 4.53E-06
SRGN Serglycin 2.2307 2.10E-05 21.8865 1.33E-06
LYVE1 Lymphatic vessel endothelial hyaluronan receptor 1 2.2275 9.19E-07 22.4155 1.90E-05
LCN6 Lipocalin 6 2.1991 2.38E-10 21.5541 2.34E-06
PCOLCE Procollagen C-endopeptidase enhancer 2.1615 2.83E-05 22.2239 1.87E-05
DARC Duffy blood group, chemokine receptor 2.1597 1.44E-09 23.5596 4.90E-06
CLDN5 Claudin 5 2.1438 1.44E-09 21.6468 7.82E-05
S1PR1 Sphingosine-1-phosphate receptor 1 2.1421 1.44E-09 21.592 2.52E-06
CCL21 Chemokine (C-C motif) ligand 21 2.1272 2.65E-07 21.9191 5.97E-05
HTATIP2 HIV-1 Tat interactive protein 2, 30 kDa 2.1085 1.19E-04 21.6651 1.88E-06
SOX18 SRY (sex determining region Y)-box 18 2.0969 9.81E-08 21.699 5.79E-05
CREG1 Cellular repressor of E1A-stimulated genes 1 2.0799 4.55E-05 21.6091 3.35E-05
PECAM1 Platelet/endothelial cell adhesion molecule 2.0659 3.79E-08 21.6298 9.27E-06
CRIM1 Cysteine rich transmembrane BMP regulator 1 2.0092 1.84E-08 21.6596 1.51E-05
1Fold change was calculated as mean methylation beadchip value for leiomyoma relative to normal myometrium.
2Fold change was calculated as mean mRNA expression microarray value for leiomyoma relative to normal myometrium.
doi:10.1371/journal.pone.0033284.t002
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expression in uterine leiomyoma and adjacent normal myometrial
tissues from 18 matched pairs, all from African American subjects
to limit biological heterogeneity, and avoid epigenetic variations
among ethnic groups. The following real-time RT-PCR validation
of mRNA expression and bisulfite sequencing validation of DNA
methylation of these genes were performed on both a subset of the
original African American samples and additional new samples
from Caucasian subjects. Additionally, in vitro cultured experi-
ments utilized primary cells from both ethnic groups. We have not
observed any apparent differences with respect to the 3 studied
genes between samples from African- and Caucasian-American
subjects suggesting that the findings may be applicable to both
ethnic groups. This conclusion, however, should be taken with
some caution due to the low number of Caucasian subjects.
Further studies are needed to make a more definitive conclusion.
Our study confirms the link between epigenetic DNA
modifications and gene expression in uterine leiomyomas, by
demonstrating the effects of promoter DNA methylation on gene
silencing, particularly in three tumor suppressors known to be
involved in reproductive tumorigenesis. Though our work is the
first to examine genome-wide analysis of DNA methylation in
uterine leiomyoma and there are no existing data against which we
can compare our results, our mRNA expression profiles are
consistent with previously published reports [17–26].
In our genome-wide analysis, we observed that 1,031 transcrip-
tional regulatory regions were differentially methylated and only
525 mRNA species were transcriptionally altered in uterine
leiomyoma compared with myometrial tissue. This degree of
mismatch between DNA methylation and steady-state mRNA
levels was expected since changes in DNA methylation may not
always lead to changes in steady-state mRNA levels for the
following potential reasons. (i) DNA methylation alone may not be
sufficient to alter mRNA expression, and other events such as
changes in the structure of chromatin formed on a methylated
template are needed to render it transcriptionally altered. (ii) The
availability and binding capacity of specific transcription factors
are needed to regulate the rate of mRNA transcription from a
gene promoter. (iii) Finally, other factors that regulate the half-life
of a certain transcript will determine its steady-state levels.
Consequently, it is expected that changes in steady-state mRNA
levels are regulated only partially by DNA methylation.
Although, we attempted to account for differences in the
menstrual cycle, the majority of the samples included in our
analysis (14/18) were obtained during the proliferative phase.
Moreover, it is challenging to date the endometrium for cycle
phase since many women with uterine leiomyomas have irregular
cycles with prolonged bleeding. The small number of secretory
phase samples did not permit us to compare biological differences
as a function of the cycle phase. Since the correlation between
differences in DNA methylation and gene expression was
evaluated in paired samples from the same patient, the effect of
cycle phase on this analysis was further minimized.
In this study, we noted a key epigenetic mechanism whereby
increased promoter methylation leads to transcriptional suppres-
sion in uterine leiomyoma compared with matched normal
myometrial tissues. The second predominant mechanism was
hypomethylation associated with overexpression of genes indicat-
ing an overall inverse relationship between DNA methylation and
gene expression in uterine leiomyoma. However, we also observed
some genes to be hypermethylated and upregulated, and other
genes to be hypomethylated and downregulated. The absence of
an inverse relationship between promoter DNA methylation and
mRNA expression in this minor group of genes is consistent with
previously published data. For example, methylation of one
particular CpG island in the NR5A1 gene is associated with
transcriptional suppression, whereas methylation of another CpG
island located 4 kb downstream is associated with overexpression
of NR5A1 mRNA [17,27]. It is conceivable that the effects of a
single methylated CpG island on gene expression may be either
gene-specific or location-specific within the same gene.
We verified the effects of promoter DNA methylation on
transcriptional inhibition of three tumor suppressor genes namely,
KLF11, DLEC1, and KRT19. KLF11 is a transcription factor
and a member of the transforming growth factor beta (TGFb)
family, which is involved in key cellular functions such as
apoptosis, proliferation, and differentiation [28]. KLF11 is
expressed in a number of human tissues, and it is repressed in
several human cancers. It inhibits neoplastic transformation and
cell growth both in vivo and in vitro [29]. We previously
demonstrated the downregulation of KLF11 expression in uterine
leiomyoma tissues compared with normal matched myometrial
tissue [30]. Although the mechanism involved in KLF11-regulated
cell proliferation is not fully understood, we demonstrated for the
Table 3. Summary of hypomethylated, transcriptionally upregulated genes in uterine leiomyoma compared with adjacent normal
myometrium (N=18 matched samples).
Gene symbol Gene name DNA Methylation
1 P-value mRNA level
2 P-value
POPDC2 Popeye domain containing 2 26.0818 3.73E-07 1.7758 1.14E-04
PCP4 Purkinje cell protein 4 24.2627 3.38E-08 3.2515 2.91E-04
IL17B Interleukin 17B 24.0467 1.66E-08 3.0582 3.46E-06
CHRDL2 Chordin-like 2 22.8997 3.19E-06 2.8911 1.43E-04
RPE65 Retinal pigment epithelium-specific 22.8382 3.57E-06 1.623 6.00E-04
PHLDB2 Pleckstrin homology-like domain, 22.6662 1.11E-10 1.5018 5.80E-05
MMP11 Matrix metallopeptidase 11 22.585 9.82E-07 4.921 1.85E-04
MFAP2 Microfibrillar-associated protein 2 22.2917 4.96E-06 2.1194 2.81E-06
JPH4 Junctophilin 4 22.2868 5.50E-08 1.5724 3.39E-06
PLP1 Proteolipid protein 1 22.1274 4.06E-04 3.3833 6.71E-05
1Fold change was calculated as mean methylation beadchip value for leiomyoma relative to normal myometrium.
2Fold change was calculated as mean mRNA expression microarray value for leiomyoma relative to normal myometrium.
doi:10.1371/journal.pone.0033284.t003
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methylation, with hypermethylation correlating with a repressed
state in uterine leiomyoma. Recently, KLF11 was also shown to be
aberrantly hypermethylated in myelodysplastic syndromes. It has
been suggested that KLF11 inhibits gene expression through a
Sin3a-HDAC interacting domain and recruitment of the core-
pressor mSin3a [31]. We plan to investigate this mechanism
further, and identify the DNMTs and DNA methyl binding
proteins that are involved in silencing of KLF11.
DLEC1 is an epigenetically modified tumor suppressor gene
[32]. DLEC1 is localized in the cytoplasm ubiquitously expressed
in all human tissues, and repressed in several human cancers.
Hypermethylation of the DLEC1 promoter is associated with its
transcriptional repression in a wide variety of malignant tumors
originating from lung, esophagus, kidney, ovary, nasopharynx,
and liver [33]. The DLEC1 promoter region contains a CpG
island in the first exon, and we demonstrated here that
methylation of this CpG is responsible for the repression of
DLEC1 expression in uterine leiomyoma. Our analysis revealed a
strong association between silencing of DLEC1 expression and
promoter hypermethylation in uterine leiomyoma; in addition,
treatment of addition of cultured primary uterine leiomyoma
smooth muscle cells with a DNMT inhibitor restored DLEC1
expression. The DLEC1 gene encodes a 166 kDa protein, whose
biologic function remains unknown due to lack of homology to any
known conserved proteins or domains [34]. In the future, we plan
to characterize the biological function of DLEC1 in uterine
leiomyoma.
KRT19 is an intermediate filament protein responsible for the
structural integrity of epithelial cells, this genes encodes a 40-kDa
protein [35]. In mammalian cells, keratin filaments are organized
in a complex network spreading from the nucleus to the
cytoplasmic membrane. KRT19 is also known as an epigenetically
regulated tumor suppressor gene, which has frequently demon-
strated promoter hypermethylation associated with transcriptional
downregulation in several cancerous tumors such as neuroblasto-
mas, squamous cell carcinoma of the head and neck region and
renal cell carcinomas [36–38]. Also, it is one of the most common
used markers for real-time RT-PCR detection of tumor cells
disseminated in lymph nodes, peripheral blood and bone marrow
of breast cancer patients [39–40].
Using genome-wide analyses of DNA methylation in uterine
leiomyoma we hope to define a specific epigenetic profile that
could inform the development of diagnostic biomarkers for uterine
leiomyoma as well as identify potential therapeutic targets.
Because DNA methylation is reversible, epigenetic modifying
drugs could be used in the medical management of uterine
leiomyoma. Importantly, aberrant DNA methylation and other
epigenetic abnormalities may represent a critical initial mechanism
that triggers transformation of a single myometrial cell that will
eventually give rise to a monoclonal leiomyoma tumor. Under-
standing the mechanism underlying the pathogenesis of uterine
leiomyoma will be critical for developing new preventive and
therapeutic approaches to the disease.
Materials and Methods
Ethics Statement
To obtain human tissues, we followed the protocol approved by
the Institutional Review Board for Human Research of North-
western University and New York University. Written informed
consent was received from all subjects.
Tissue acquisition
For in vivo studies, we obtained matched pairs of leiomyoma and
adjacent myometrium from a total of 23 African American and 14
Caucasian-American subjects undergoing hysterectomy for symp-
tomatic fibroids. To minimize heterogeneity due to race we used
samples from 18 African American subjects for both genome-wide
DNA methylation and gene expression microarrays. In follow-up
verification studies, we included samples from 4 of the original
African American group plus 4 additional Caucasian subjects for
bisulfite sequencing and all 18 original African American plus 10
Caucasian subjects for mRNA quantification using real-time RT-
PCR. Samples from Caucasian subjects were added to evaluate
whether similar patterns of DNA methylation and mRNA
expression were observed.
Key clinical characteristics of the 18 African American subjects,
whose samples were used for both microarrays are described in
Table 1. The clinical characteristics of Caucasian subjects fall
within the range depicted in Table 1. All African- or Caucasian-
American subjects were premenopausal women (mean age 44
years; range 30–50 years), and the tumor sizes ranged from 5 to
17 cm in diameter. The subjects had not received any hormonal
treatment for at least 6 months prior to surgery. The cycle phase
was estimated by the last menstrual period and was confirmed by
endometrial histology. Each leiomyoma tissue biopsy was obtained
at 1 cm from the outer capsule of the tumor. The matched
myometrial sample was taken at 2 cm from the tumor in the
fundal portion of the uterus. All tissue samples were snap-frozen in
liquid nitrogen before DNA and RNA isolation. The leiomyoma
and myometrial tissue specimens were biopsied by a pathologist
under the supervision of Dr. Wei, who is a board-certified
pathologist. Dr. Wei and his pathology team carefully examined
these specimens both grossly and histologically and made sure that
they were not contaminated by endometrial stroma or epithelium.
The initial sample size of 18 pairs for microarray platforms was
derived from the power analysis based on published clinical
studies, which showed that significant differences for most
dysregulated gene products can be detected with sample size of
13 to 22 subjects per group with 80% power and 0.05 alpha levels
[41].
Primary cell isolation
Leiomyoma smooth muscle cells were isolated from the
peripheral portions approximately 1 cm from the outer capsule
of the leiomyoma, and then cultured as previously described with
minor modifications [42]. Cells were cultured in DMEM/F12 1:1
(GIBCO/BRL, Grand Island, NY) containing 10% fetal bovine
Figure 2. Differential patterns of DNA methylation and mRNA expression in uterine leiomyoma and matched myometrial tissues.
Overall, 36 samples from 18 subjects were analyzed; 18 samples were obtained from leiomyomas and 18 from adjacent matched myometrial tissues.
(A) The DNA methylation profile shows that most of the samples exhibit a very homogeneous DNA methylation pattern. (B) The gene expression
profile exhibits a less homogeneous pattern, which could be due to mRNA instability. (C) Functional analysis of the 55 genes with correlation
between DNA methylation status and mRNA expression showed that the top two functions represented are cancer processes (P,10
212) and
reproductive system disease (P,10
28).
doi:10.1371/journal.pone.0033284.g002
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atmosphere with 5% CO2 at 37uC. Primary cells were used only
up to the second passage to avoid changes in phenotype and gene
expression.
DNA methylation and mRNA expression analysis
Genomic DNA was isolated from 20 mg frozen tissues using the
DNeasy Blood & Tissue (Qiagen, Valencia, CA). One microgram
of genomic DNA from each sample was bisulfite-modified using
Figure 3. DNA methylation status of KLF11, DLEC1, and KRT19 promoters in uterine leiomyoma and matched myometrial tissues.
(A) DNA methylation status of 16 CpG sites in the KLF11 promoter region obtained from bisulfite sequencing of uterine leiomyoma and matched
myometrial tissues. The numbers 1 to 8 on the side represent subjects from whom tissues were obtained, (#1–4) subjects were African Americans
included in our original genome-wide DNA methylation study and we incorporated 4 new matched samples from Caucasian subjects (#5–8). Black
circles represent methylated cytosines and white represent unmethylated cytosines. Numbers indicate the position of cytosine residues of CpGs
relative to the transcription start site (+1). (B) Percent DNA methylation of the KLF11 promoter region in uterine leiomyoma and myometrial tissues,
P,0.003. (C) DNA methylation status of 18 CpG sites in the DLEC1 promoter region from 3 African American (#1–3) and 4 Caucasian subjects (#4–7).
(D) Percent DNA methylation of the DLEC1 promoter region in uterine leiomyoma and myometrial tissues, P,0.003. (E) DNA methylation status of 30
CpG sites in the KRT19 promoter region from 4 African American (#1–4) and 3 Caucasian subjects (#4–7). (F) Percent DNA methylation of the KRT19
promoter region in uterine leiomyoma and myometrial tissues, P,0.001.
doi:10.1371/journal.pone.0033284.g003
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according to the manufacturer’s protocol along with the technical
validation of the assay [12]. Bisulfite-modified DNA was
hybridized to the HumanMethylation27 Beadchip (Illumina Inc.,
San Diego, CA).
Total RNA was isolated from 20 mg of frozen tissues using the
RNeasy Fibrous Tissue kit (Qiagen) according to manufacturer
protocols with minor modifications. After elution, RNA samples
were quantified using a ND-1000 spectrophotometer (NanoDrop
Wilmington, DE) and evaluated for degradation using a 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA). For use in
hybridization, samples were required to have a RIN.9, an
OD260/280 of 1.9–2.0, and OD260/230.1.5, and a 28S:18S
ribosomal band ratio of .1.5. The samples were hybridized into
the HumanHT-12 v3 genome-wide gene expression BeadChips
according to the manufacturer’s protocol (Illumina, Inc.).
We used the Bioconductor lumi [43] package, which was developed
by our collaborator and is widely used as one of the standard tools to
process both Illumina DNA methylation and mRNA expression data.
T h ed a t af i r s tw e n tt h r o u g haQ A / Q Cs t e p .F o rI l l u m i n ae x p r e s s i o n
data, the data passing QA step was preprocessed using a variance
stabilization transformation method [44] followed by quantile
normalization. For methylation data, we first performed a color
balance adjustment of methylated and unmethylated probe intensities
between two color channels using a smooth quantile normalization
method. The methylated and unmethylated probe intensities were
then normalized using the SSN (Scale and Shift Normalization)
method. The methylation M-value (log 2 ratio of methylated and
unmethylated probes) was calculated to estimate the methylation level
of the measured CpG sites [45]. The follow-up analysis was then based
on the M-value. We used a shift and scaling normalization (SSN)
method, which includes global background shift during normalization
instead of more aggresive quantile normalization as described in
reference 45. We made this decision primarily because we produced
high quality and consistent data evident by the principal component
analysis that we are now incorporating in the supplemental section.
After preprocessing, the differential analysis of methylation data was
similar to that used for expression microarray data. Probes (for
expression data) or CpG-sites (for methylation data) with all samples
‘‘Absent’’ (lower or around background levels) were removed from
Figure 4. mRNA levels of KLF11, DLEC1 and KRT19 in uterine leiomyoma and matched adjacent myometrial tissues. mRNA levels of
(A) KLF11, (B) DLEC1, and (C) KRT19 were quantified using all 18 samples used in microarrays plus the addition of 7–10 new Caucasian samples. mRNA
levels in leiomyoma and matched myometrium were quantified by real-time PCR, they were first normalized to GAPDH. Then, to allow comparisons
of data obtained from samples from different subjects, mRNA levels in the myometrial tissues were normalized to 1. KLF11 (n=25; P,0.0001), DLEC1
(n=28; P,0.0001) and KRT19 (n=25; P,0.0001). The data are shown as the mean +/2 SEM. P,0.05 versus myometrium tissues.
doi:10.1371/journal.pone.0033284.g004
Figure 5. Effect of DNMT inhibitor 5-aza-dC on KLF11, DLEC1 and KRT19 expression in leiomyoma smooth muscle cells. (A) KLF11, (B)
DLEC1 and (C) KRT19 mRNA levels were quantified by real-time RT-PCR after treatment of cultured uterine leiomyoma smooth muscle cells with
vehicle or 5-aza-dC (3 mM) for 5 days. mRNA levels were normalized first to GAPDH and then, to those in vehicle-treated cells. Experiments were
performed in triplicate samples, and the data are representative of samples from seven different subjects. The data are shown as the mean +/2 SEM.
P,0.05 as compared with vehicle treatment.
doi:10.1371/journal.pone.0033284.g005
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both methylation and expression between leiomyoma and myometrial
tissues, we performed differential analyses using routines implemented
in the limma package [46]. To ensure both high statistical significance
and strong biological effects, we require that the differentially
methylated CpG sites had an FDR,0.01 and fold-change (based on
M-value) of .2; using this process 1031 CpG sites (585 up, 446 down)
were identified. For mRNA expression data, we required that the
differentially expressed genes had an FDR,0.01 and a fold-change
of.1.5; with these parameters, we identified 525 genes (218 up, 307
down). We mapped the differentially methylated CpG sites to the
closest downstream gene, and found there are 55 overlapping genes
between the lists of genes with changes in DNA methylation and
mRNA expression data. The microarray data is MIAME compliant
and is available at the Gene Expression Omnibus Web site (http://
www.ncbi.nlm.nih.gov/geo) under accession No.GSE31699.
Bisulfite genomic sequencing
To confirm DNA methylation levels by bisulfite sequencing, 500 ng
of gDNA was treated with sodium bisulfite according to the
manufacturer’s instructions (Zymo Research, Orange, CA). For PCR
amplification, 3 ml of bisulfite-treated DNA was added to a final
volume of 20 ml. ZymoTaq PreMix (Zymo Research, Orange, CA)
was used for all PCR reactions. The thermal cycler conditions were as
follows: 95uC for 10 min then 40 cycles of denaturation at 95uCf o r
30 sec, annealing at 50uC for 2 min, and elongation at 72uCf o r2m i n ,
followed by an extension at 72uC for 7 min. PCR products were gel
purified and cloned into the PCR 2.1 vector (Invitrogen, Carlsbad,
CA). After transformation, 10 clones were sequenced on the Applied
Biosystems 377 instrument. Methylation sites were visualized and
quality control was performed using the QUMA software (http://
quma.cdb/riken.jp/) and Biq analyzer.
Real-time quantitative RT-PCR
Total RNA from fresh tissues and leiomyoma smooth muscle cells
was extracted using Tri-reagent (Sigma-Aldrich, St. Louis, MO) and
the RNeasy Fibrous Tissue kit (Qiagen). cDNA was prepared with
qScript cDNA Supermix (Quanta BioSciences, Inc., Gaithersburg,
MD) from 2 mg of RNA. Primers against KLF11 and DLEC1 and the
constitutively expressed glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were used as described in previous reports. Primer specificity
was confirmed by the demonstration of single peaks using dissociation
curves after amplification of cDNA and a lack of amplification of
genomic DNA. Real-time PCR was performed to determine the
relative amounts of each transcript using the DNA-binding dye SYBR
green (Applied Biosystems, Foster City, CA) and the ABI Prism
7900HT Detection System (Applied Biosystems). Cycling conditions
started at 50 C for 2 min, followed by 95uC for 10 min, then 40 cycles
of 95uC for 15 sec and 60uC for 1 min. The cycle threshold (Ct) was
placed at a set level where the exponential increase in PCR
amplification was approximately parallel between all samples. Relative
fold change was calculated by comparing Ct values between the target
gene and GAPDH as the reference guide. The primer sequences used
were: KLF11: forward: 59-CACGATGCACACGCCGGACT-39;
reverse: 59-TCGCTGTCATGCCGCTTCCT-39;D L E C 1 :f o r w a r d :
59-GACGAAGTGAGCGCAAGC-39;r e v e r s e :5 9-ATCCAGCCG-
CTGCTTATAGA-39; GAPDH: forward: 59-GAAGGTGAAGG-
TCGGAGTC-39; reverse: 59-GAAGATGGTGATGGGATTTC-39;
The DDCt method was used to analyze the relative changes in gene
expression.
5-aza-29-deoxycytidine (5-aza-dC) treatment
Monolayer cultures at approximately 40% confluence were starved
in serum-free medium overnight and treated with vehicle (DMSO
1:1000) or 0.5, 1, 3, 5, 10, 15, or 20 mM of the DNMT inhibitor 5-aza-
dC (Sigma-Aldrich) for 5 days. The medium was changed every
24 hrs. Total RNA was isolated using Tri-reagent (Sigma-Aldrich). All
of the experiments were repeated in triplicate using samples from at
least 7 new different subjects not previously used in microarrays, 4
subjects were African- and 3 Caucasian-American.
Protein Analysis
Protein was extracted from 50 mg of frozen tissues using
mammalian protein extraction reagent (Pierce, Rockford, IL).
Figure 6. Protein levels of KLF11, DLEC1 and KRT19 in uterine leiomyoma and matched adjacent myometrial tissues. Protein levels of
KLF11, DLEC1 and KRT19 in leiomyoma and matched myometrium were analyzed by immunoblotting. (A–C) Western blots are representative of
several experiments repeated in at least 6 subjects. (D–F) Protein quantification using ImageJ software shows that there is lower expression of KLF11
(n=6, P,0.0001), DLEC1 (n=9, P,0.005) and KRT19 (n=8, P,0.03) (Student’s t-test) in leiomyoma compared to matched adjacent myometrial
tissues. GAPDH was used as a loading control. M=myometrial tissue; L=leiomyoma tissue.
doi:10.1371/journal.pone.0033284.g006
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Equal amounts of protein (30 ug) were resolved on 4–12% Ready
Gel Precast Gels (Bio-Rad Laboratories, Hercules, CA), and
transferred onto PVDF membranes. The membranes were bloted
with antihuman KLF11 antibodies 1:1000 (Cell Signaling),
DLEC1 1:500 (Sigma-aldrich), and KRT19 1:1000 (Cell Signal-
ing). Anti-GAPDH antibody was used as a loading control.
Dectection was detected using a Supersignal West Femto (Pierce).
Quantification of the immunoblots was done using ImageJ
software and normalized to GAPDH.
Statistical analysis
Statistical significance was determined by Student’s t test and
one-way ANOVA followed by Fisher’s protected least significant
difference test. Significance was accepted at P,0.05.
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